score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2024	168.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	ACC_UNION	TCGA-OR-A5LK-01A-11D-A29I-10	TCGA-OR-A5LK-10A-01D-A29L-10
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594G	0.3425	73.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.D594G (Missense)	1	ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.V159M	0.0755	212.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.V159M (Missense)	1	ACC_UNION	TCGA-OR-A5KZ-01A-11D-A29I-10	TCGA-OR-A5KZ-10A-01D-A29L-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R377K	0.5652	115.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R377K (Missense)	1	ACC_UNION	TCGA-OR-A5K0-01A-11D-A29I-10	TCGA-OR-A5K0-10B-01D-A29L-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.Y872D	0.4593	172.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.Y872D (Missense)	0	ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R23*	0.9244	119.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R23* (Nonsense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R23*	0.9223	103.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R23* (Nonsense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.S629Tfs*20	0.359	39.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S629Tfs*20 (Frameshift)		ACC_UNION	TCGA-OR-A5KP-01A-11D-A30A-10	TCGA-OR-A5KP-10A-01D-A30A-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.T1011Kfs*7	0.8448	58.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.T1011Kfs*7 (Frameshift)		ACC_UNION	TCGA-OR-A5LT-01A-11D-A29I-10	TCGA-OR-A5LT-10A-01D-A29L-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.T1011Kfs*7	0.8919	74.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.T1011Kfs*7 (Frameshift)		ACC_UNION	TCGA-OR-A5LT-01A-11D-A29I-10	TCGA-OR-A5LT-10A-01D-A29L-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.V425A	0.2737	95.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.V425A (Missense)		ACC_UNION	TCGA-OR-A5J4-01A-11D-A29I-10	TCGA-OR-A5J4-10A-01D-A29L-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G597V	0.4333	30.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G597V (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2105	114.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	ACC_UNION	TCGA-P6-A5OG-01A-22D-A29I-10	TCGA-P6-A5OG-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G443C	0.4194	62.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G443C (Missense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S445F	0.2336	107.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S445F (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V345L	0.2687	134.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V345L (Missense)	1	ACC_UNION	TCGA-P6-A5OG-01A-22D-A29I-10	TCGA-P6-A5OG-10A-01D-A29L-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q542*	0.1466	116.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q542* (Nonsense)		ACC_UNION	TCGA-P6-A5OG-01A-22D-A29I-10	TCGA-P6-A5OG-10A-01D-A29L-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.H525Y	0.1471	102.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.H525Y (Missense)		ACC_UNION	TCGA-OR-A5L6-01A-11D-A29I-10	TCGA-OR-A5L6-10C-01D-A29L-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S3027I	0.6136	44.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S3027I (Missense)	1	ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R651Q	0.0857	140.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R651Q (Missense)	0	ACC_UNION	TCGA-OR-A5LJ-01A-11D-A29I-10	TCGA-OR-A5LJ-10A-01D-A29L-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.L156F	0.4272	103.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.L156F (Missense)	0	ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.K114R	0.1564	307.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.K114R (Missense)	0	ACC_UNION	TCGA-OR-A5K5-01A-11D-A29I-10	TCGA-OR-A5K5-10A-01D-A29L-10
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.D179G	0.4615	117.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.D179G (Missense)	0	ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.T457M	0.2348	264.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.T457M (Missense)		ACC_UNION	TCGA-OR-A5J5-01A-11D-A29I-10	TCGA-OR-A5J5-10A-01D-A29L-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.T457R	0.1915	282.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.T457R (Missense)		ACC_UNION	TCGA-OR-A5K2-01A-11D-A29I-10	TCGA-OR-A5K2-10B-01D-A29L-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.Q390R	0.6341	82.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.Q390R (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S121F	0.4737	76.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.S121F (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E339Afs*8	0.2421	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E339Afs*8 (Frameshift)		ACC_UNION	TCGA-OR-A5JP-01A-11D-A29I-10	TCGA-OR-A5JP-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E339*	0.8649	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E339* (Nonsense)		ACC_UNION	TCGA-OR-A5KO-01A-11D-A29I-10	TCGA-OR-A5KO-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E339*	0.8529	102.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E339* (Nonsense)		ACC_UNION	TCGA-OR-A5KO-01A-11D-A29I-10	TCGA-OR-A5KO-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337H	0.9388	98.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337H (Missense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337H	0.9333	90.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337H (Missense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R335Lfs*10	0.6905	84.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R335Lfs*10 (Frameshift)		ACC_UNION	TCGA-OR-A5JL-01A-11D-A29I-10	TCGA-OR-A5JL-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.8571	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.8636	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275S	0.7857	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275S (Missense)		ACC_UNION	TCGA-OR-A5JJ-01A-11D-A29I-10	TCGA-OR-A5JJ-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275S	0.8049	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275S (Missense)		ACC_UNION	TCGA-OR-A5JJ-01A-11D-A29I-10	TCGA-OR-A5JJ-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.9296	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		ACC_UNION	TCGA-OR-A5J5-01A-11D-A29I-10	TCGA-OR-A5J5-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.9359	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		ACC_UNION	TCGA-OR-A5J5-01A-11D-A29I-10	TCGA-OR-A5J5-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y234C	0.4686	175.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y234C (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8598	107.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		ACC_UNION	TCGA-OR-A5LJ-01A-11D-A29I-10	TCGA-OR-A5LJ-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8561	132.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		ACC_UNION	TCGA-OR-A5LJ-01A-11D-A29I-10	TCGA-OR-A5LJ-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173L	0.411	163.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173L (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.H168Cfs*8	0.6207	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H168Cfs*8 (Frameshift)		ACC_UNION	TCGA-OR-A5J2-01A-11D-A29I-10	TCGA-OR-A5J2-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C135Y	0.7172	99.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C135Y (Missense)		ACC_UNION	TCGA-OR-A5KY-01A-11D-A29I-10	TCGA-OR-A5KY-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132N	0.2093	86.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132N (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.8557	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		ACC_UNION	TCGA-OR-A5JG-01A-11D-A29I-10	TCGA-OR-A5JG-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.856	125.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		ACC_UNION	TCGA-OR-A5JG-01A-11D-A29I-10	TCGA-OR-A5JG-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V73Rfs*76	0.75	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V73Rfs*76 (Frameshift)		ACC_UNION	TCGA-PK-A5HC-01A-11D-A30A-10	TCGA-PK-A5HC-11A-11D-A30A-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E56*	0.3636	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E56* (Nonsense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P27Lfs*17	0.9048	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27Lfs*17 (Frameshift)		ACC_UNION	TCGA-OR-A5LE-01A-11D-A29I-10	TCGA-OR-A5LE-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P27Lfs*17	0.9	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27Lfs*17 (Frameshift)		ACC_UNION	TCGA-OR-A5LE-01A-11D-A29I-10	TCGA-OR-A5LE-10A-01D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X25_splice	0.3704	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X25_splice (Splice Site)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G265C	0.6154	13.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G265C (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.V657M	0.4375	96.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.V657M (Missense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.V761M	0.1773	141.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.V761M (Missense)		ACC_UNION	TCGA-P6-A5OH-01A-11D-A30A-10	TCGA-P6-A5OH-11A-01D-A30A-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.C897S	0.5778	45.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.C897S (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S932I	0.5882	17.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S932I (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.M1231T	0.3485	264.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.M1231T (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.V184F	0.5862	58.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.V184F (Missense)		ACC_UNION	TCGA-OR-A5J8-01A-11D-A29I-10	TCGA-OR-A5J8-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.E1611*	0.0813	123.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.E1611* (Nonsense)		ACC_UNION	TCGA-OR-A5J2-01A-11D-A29I-10	TCGA-OR-A5J2-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.I328V	0.5	20.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.I328V (Missense)		ACC_UNION	TCGA-OR-A5J9-01A-11D-A29I-10	TCGA-OR-A5J9-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D908H	0.0426	305.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D908H (Missense)		ACC_UNION	TCGA-OR-A5K6-01A-11D-A29I-10	TCGA-OR-A5K6-10A-01D-A29L-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Insertion	p.V733_L734insFFF	0.1607	112.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V733_L734insFFF (Insertion)	0	ACC_UNION	TCGA-OR-A5LE-01A-11D-A29I-10	TCGA-OR-A5LE-10A-01D-A29L-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.A155V	0.7625	80.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.A155V (Missense)	1	ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.A155V	0.75	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.A155V (Missense)	1	ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.N184I	0.0673	223.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.N184I (Missense)	0	ACC_UNION	TCGA-OR-A5L2-01A-11D-A30A-10	TCGA-OR-A5L2-10A-01D-A30A-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Nonsense	p.R95*	0.9583	48.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.R95* (Nonsense)	0	ACC_UNION	TCGA-OR-A5LB-01A-11D-A29I-10	TCGA-OR-A5LB-10A-01D-A29L-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Nonsense	p.R95*	0.9592	49.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.R95* (Nonsense)	0	ACC_UNION	TCGA-OR-A5LB-01A-11D-A29I-10	TCGA-OR-A5LB-10A-01D-A29L-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.I1662M	0.0493	223.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.I1662M (Missense)		ACC_UNION	TCGA-PK-A5HC-01A-11D-A30A-10	TCGA-PK-A5HC-11A-11D-A30A-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Insertion	p.Q904_D905insEASVLQGYKNRNQ	0.3	30.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.Q904_D905insEASVLQGYKNRNQ (Insertion)		ACC_UNION	TCGA-OR-A5J7-01A-11D-A29I-10	TCGA-OR-A5J7-10A-01D-A29L-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.V1557D	0.4371	167.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.V1557D (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.T127S	0.5542	83.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.T127S (Missense)	0	ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.S62R	0.3529	187.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.S62R (Missense)		ACC_UNION	TCGA-OR-A5L3-01A-11D-A29I-10	TCGA-OR-A5L3-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.S271F	0.4773	44.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.S271F (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.E842Vfs*3	0.8046	87.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.E842Vfs*3 (Frameshift)		ACC_UNION	TCGA-OR-A5LJ-01A-11D-A29I-10	TCGA-OR-A5LJ-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.R495*	0.9146	164.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R495* (Nonsense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.R495*	0.9091	154.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R495* (Nonsense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.A749S	0.13	100.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.A749S (Missense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Splice Site	p.X1172_splice	0.3023	43.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.X1172_splice (Splice Site)		ACC_UNION	TCGA-OR-A5J4-01A-11D-A29I-10	TCGA-OR-A5J4-10A-01D-A29L-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Frameshift	p.P381Qfs*42	0.4268	82.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P381Qfs*42 (Frameshift)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability	Preclinical			Somatic Variant	MPL	Frameshift	p.K573Qfs*40	0.2151	186.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.K573Qfs*40 (Frameshift)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A203V	0.3866	119.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A203V (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Splice Site	p.X1069_splice	0.0133	75.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.X1069_splice (Splice Site)	0	ACC_UNION	TCGA-OR-A5KU-01A-11D-A29I-10	TCGA-OR-A5KU-10A-01D-A29L-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Frameshift	p.R906Dfs*47	0.3971	204.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R906Dfs*47 (Frameshift)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.E180_D184del	0.7941	136.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E180_D184del (Deletion)		ACC_UNION	TCGA-OR-A5KZ-01A-11D-A29I-10	TCGA-OR-A5KZ-10A-01D-A29L-10
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P774A	0.4907	216.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P774A (Missense)		ACC_UNION	TCGA-OR-A5LG-01A-11D-A29I-10	TCGA-OR-A5LG-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.D241G	0.196	347.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.D241G (Missense)		ACC_UNION	TCGA-OR-A5LI-01A-11D-A30A-10	TCGA-OR-A5LI-10A-01D-A30A-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1813H	0.9349	169.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1813H (Missense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1813H	0.929	155.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1813H (Missense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.F70L	0.2268	97.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.F70L (Missense)		ACC_UNION	TCGA-OR-A5LR-01A-11D-A29I-10	TCGA-OR-A5LR-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.Q69E	0.3591	401.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.Q69E (Missense)		ACC_UNION	TCGA-OU-A5PI-01A-12D-A29I-10	TCGA-OU-A5PI-10A-01D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.A971V	0.9118	68.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.A971V (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.A971V	0.9375	48.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.A971V (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.C79Y	0.4746	118.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.C79Y (Missense)		ACC_UNION	TCGA-OR-A5J4-01A-11D-A29I-10	TCGA-OR-A5J4-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.Y30*	0.4633	218.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.Y30* (Nonsense)		ACC_UNION	TCGA-OR-A5J2-01A-11D-A29I-10	TCGA-OR-A5J2-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.2289	249.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		ACC_UNION	TCGA-OR-A5JS-01A-11D-A29I-10	TCGA-OR-A5JS-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.8736	87.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		ACC_UNION	TCGA-OR-A5LJ-01A-11D-A29I-10	TCGA-OR-A5LJ-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.8889	108.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		ACC_UNION	TCGA-OR-A5LJ-01A-11D-A29I-10	TCGA-OR-A5LJ-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34V	0.3366	202.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34V (Missense)		ACC_UNION	TCGA-OR-A5K5-01A-11D-A29I-10	TCGA-OR-A5K5-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.A39Efs*3	0.3589	209.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.A39Efs*3 (Frameshift)		ACC_UNION	TCGA-OR-A5K6-01A-11D-A29I-10	TCGA-OR-A5K6-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.3797	158.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		ACC_UNION	TCGA-OR-A5KU-01A-11D-A29I-10	TCGA-OR-A5KU-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.S45_P52del	0.3258	132.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45_P52del (Deletion)		ACC_UNION	TCGA-OR-A5K9-01A-11D-A29I-10	TCGA-OR-A5K9-11A-11D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.S45del	0.3143	140.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45del (Deletion)		ACC_UNION	TCGA-OR-A5JM-01A-11D-A29I-10	TCGA-OR-A5JM-10B-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.527	148.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		ACC_UNION	TCGA-OR-A5JY-01A-31D-A29I-10	TCGA-OR-A5JY-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3438	128.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		ACC_UNION	TCGA-OR-A5L1-01A-11D-A30A-10	TCGA-OR-A5L1-10A-01D-A30A-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.4219	128.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		ACC_UNION	TCGA-OR-A5L3-01A-11D-A29I-10	TCGA-OR-A5L3-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3836	146.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		ACC_UNION	TCGA-OR-A5L8-01A-11D-A29I-10	TCGA-OR-A5L8-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.4815	162.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		ACC_UNION	TCGA-OR-A5LE-01A-11D-A29I-10	TCGA-OR-A5LE-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.8	95.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		ACC_UNION	TCGA-OR-A5JJ-01A-11D-A29I-10	TCGA-OR-A5JJ-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.8592	71.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		ACC_UNION	TCGA-OR-A5JJ-01A-11D-A29I-10	TCGA-OR-A5JJ-10A-01D-A29L-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R146S	0.1769	130.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R146S (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.A409V	0.1988	347.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.A409V (Missense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R260M	0.1301	146.0	0.0	0.0																									NTRK1 p.R260M (Missense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.N149D	0.4167	120.0	0.0	0.0																									FGFR2 p.N149D (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P242H	0.4054	74.0	0.0	0.0																									FLI1 p.P242H (Missense)		ACC_UNION	TCGA-OR-A5J4-01A-11D-A29I-10	TCGA-OR-A5J4-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	MDM2	Nonsense	p.R71*	0.3378	74.0	0.0	0.0																									MDM2 p.R71* (Nonsense)		ACC_UNION	TCGA-OR-A5K4-01A-11D-A29I-10	TCGA-OR-A5K4-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	MDM2	Missense	p.E430Q	0.4899	347.0	0.0	0.0																									MDM2 p.E430Q (Missense)		ACC_UNION	TCGA-OR-A5JG-01A-11D-A29I-10	TCGA-OR-A5JG-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q217*	0.75	32.0	0.0	0.0																									RB1 p.Q217* (Nonsense)		ACC_UNION	TCGA-OR-A5JS-01A-11D-A29I-10	TCGA-OR-A5JS-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E458*	0.5946	37.0	0.0	0.0																									RB1 p.E458* (Nonsense)		ACC_UNION	TCGA-OR-A5JE-01A-11D-A29I-10	TCGA-OR-A5JE-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.M731I	0.5412	85.0	0.0	0.0																									NTRK3 p.M731I (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P401Q	0.3873	204.0	0.0	0.0																									NTRK3 p.P401Q (Missense)		ACC_UNION	TCGA-OR-A5KY-01A-11D-A29I-10	TCGA-OR-A5KY-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P304T	0.1905	42.0	0.0	0.0																									NTRK3 p.P304T (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Biologically Relevant				Somatic Variant	AURKB	Missense	p.R123H	0.2727	88.0	0.0	0.0																									AURKB p.R123H (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.L356Q	0.75	28.0	0.0	0.0																									NF1 p.L356Q (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.L356Q	0.7222	36.0	0.0	0.0																									NF1 p.L356Q (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X775_splice	0.7381	84.0	0.0	0.0																									NF1 p.X775_splice (Splice Site)		ACC_UNION	TCGA-OR-A5KZ-01A-11D-A29I-10	TCGA-OR-A5KZ-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E1198*	0.6245	229.0	0.0	0.0																									NF1 p.E1198* (Nonsense)		ACC_UNION	TCGA-OR-A5J8-01A-11D-A29I-10	TCGA-OR-A5J8-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1235*	0.6526	95.0	0.0	0.0																									NF1 p.Q1235* (Nonsense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.N1861Kfs*6	0.7391	46.0	0.0	0.0																									NF1 p.N1861Kfs*6 (Frameshift)		ACC_UNION	TCGA-OR-A5JW-01A-11D-A29I-10	TCGA-OR-A5JW-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.R1970Efs*9	0.6279	86.0	0.0	0.0																									NF1 p.R1970Efs*9 (Frameshift)		ACC_UNION	TCGA-OR-A5LF-01A-11D-A30A-10	TCGA-OR-A5LF-10A-01D-A30A-10
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2002*	0.65	40.0	0.0	0.0																									NF1 p.Q2002* (Nonsense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E2155*	0.6889	45.0	0.0	0.0																									NF1 p.E2155* (Nonsense)		ACC_UNION	TCGA-OR-A5JP-01A-11D-A29I-10	TCGA-OR-A5JP-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L2419Gfs*2	0.4643	28.0	0.0	0.0																									NF1 p.L2419Gfs*2 (Frameshift)		ACC_UNION	TCGA-OR-A5LA-01A-11D-A29I-10	TCGA-OR-A5LA-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.N80S	0.1774	62.0	0.0	0.0																									COL1A1 p.N80S (Missense)		ACC_UNION	TCGA-OR-A5JE-01A-11D-A29I-10	TCGA-OR-A5JE-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.V465M	0.1085	258.0	0.0	0.0																									KEAP1 p.V465M (Missense)		ACC_UNION	TCGA-P6-A5OH-01A-11D-A30A-10	TCGA-P6-A5OH-11A-01D-A30A-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.L153V	0.2324	469.0	0.0	0.0																									KEAP1 p.L153V (Missense)		ACC_UNION	TCGA-OU-A5PI-01A-12D-A29I-10	TCGA-OU-A5PI-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	AURKA	Missense	p.V27M	0.5051	99.0	0.0	0.0																									AURKA p.V27M (Missense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	ERG	Missense	p.P59R	0.3438	320.0	0.0	0.0																									ERG p.P59R (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	MLH1	Deletion	p.E71del	0.8409	44.0	0.0	0.0																									MLH1 p.E71del (Deletion)		ACC_UNION	TCGA-OR-A5LB-01A-11D-A29I-10	TCGA-OR-A5LB-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.E558*	0.75	44.0	0.0	0.0																									MLH1 p.E558* (Nonsense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.E558*	0.7812	32.0	0.0	0.0																									MLH1 p.E558* (Nonsense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	TACC3	Missense	p.D709Y	0.1524	105.0	0.0	0.0																									TACC3 p.D709Y (Missense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S449P	0.4386	57.0	0.0	0.0																									PDGFRB p.S449P (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T1473A	0.4286	182.0	0.0	0.0																									ROS1 p.T1473A (Missense)		ACC_UNION	TCGA-PK-A5HB-01A-11D-A29I-10	TCGA-PK-A5HB-11A-11D-A29L-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H624Y	0.3234	167.0	0.0	0.0																									ROS1 p.H624Y (Missense)		ACC_UNION	TCGA-OR-A5KB-01A-11D-A30A-10	TCGA-OR-A5KB-11A-11D-A30A-10
Biologically Relevant				Somatic Variant	PMS2	Splice Site	p.X725_splice	0.2808	381.0	0.0	0.0																									PMS2 p.X725_splice (Splice Site)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.L378M	0.2211	95.0	0.0	0.0																									PMS2 p.L378M (Missense)		ACC_UNION	TCGA-PK-A5HA-01A-11D-A29I-10	TCGA-PK-A5HA-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	POT1	Nonsense	p.S303*	0.2515	167.0	0.0	0.0																									POT1 p.S303* (Nonsense)		ACC_UNION	TCGA-OR-A5JA-01A-11D-A29I-10	TCGA-OR-A5JA-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	POT1	Missense	p.R137L	0.3586	251.0	0.0	0.0																									POT1 p.R137L (Missense)		ACC_UNION	TCGA-OR-A5JB-01A-11D-A29I-10	TCGA-OR-A5JB-10A-01D-A29L-10
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.A30Gfs*18	0.3636	22.0	0.0	0.0																									CDKN2A p.A30Gfs*18 (Frameshift)		ACC_UNION	TCGA-OR-A5JM-01A-11D-A29I-10	TCGA-OR-A5JM-10B-01D-A29L-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.L667V	0.2437	119.0	0.0	0.0																									NTRK2 p.L667V (Missense)		ACC_UNION	TCGA-OR-A5JX-01A-11D-A29I-10	TCGA-OR-A5JX-10B-01D-A29L-10
Biologically Relevant				Microsatellite Stability	Supporting variants		RNF43 p.L12Dfs*22 (Frameshift), MSH2 p.E842Vfs*3 (Frameshift), MSH6 p.R495* (Nonsense), MLH1 p.E71del (Deletion), MLH1 p.E558* (Nonsense), PMS2 p.X725_splice (Splice Site)																													Supporting variants: RNF43 p.L12Dfs*22 (Frameshift), MSH2 p.E842Vfs*3 (Frameshift), MSH6 p.R495* (Nonsense), MLH1 p.E71del (Deletion), MLH1 p.E558* (Nonsense), PMS2 p.X725_splice (Splice Site)		ACC_UNION		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.759																													COSMIC Signature (version 2) 1 (76%)		ACC_UNION		
